AAV Gene Therapy for PGM1 Deficiency Cardiac Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human phosphoglucomutase I (PGM1) deficiency is a rare genetic disorder with severe phenotypes, including dilated cardiomyopathy and exercise intolerance, for which current treatments like dietary galactose supplementation are insufficient and may have long-term harmful effects, and no cure exists.
Innovation Solution
Development of recombinant adeno-associated virus (AAV) vectors containing a codon-optimized nucleotide sequence encoding human phosphoglucomutase 1 (hPGM1) for gene therapy, specifically targeting cardiac tissues to restore PGM1 enzyme activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary d-galactose supplementation is used to treat PGM1 deficiency, then protein glycosylation profiles improve and some symptoms are relieved, but the treatment is only efficacious for a few of the 21 phenotypes and may have long-term harmful effects
Solution Approach 1:
The patent uses AAV vectors as intermediaries to deliver the PGM1 gene directly to cardiac tissues, bypassing the limitations of dietary galactose supplementation. This viral vector system serves as a mediator that can specifically target and restore PGM1 enzyme activity in affected tissues, providing a more comprehensive and reliable treatment approach that addresses multiple phenotypes simultaneously.
Solution Approach 2:
The patent changes the fundamental parameter of treatment delivery from dietary supplementation to genetic therapy using codon-optimized PGM1 sequences. This parameter change enables the treatment to address the root cause of the disease by restoring the deficient enzyme through gene replacement, rather than attempting to compensate for the deficiency through substrate supplementation, thereby expanding treatment coverage to all 21 phenotypes.
2Object-affected harmful factors
If no treatment is provided for PGM1 deficiency, then the disease progresses with severe phenotypes including dilated cardiomyopathy and exercise intolerance, but current treatments are insufficient and may have long-term harmful effects
Solution Approach 1:
The patent segments the treatment approach by using tissue-specific promoters (such as cardiac-specific promoters) to drive PGM1 expression only in affected tissues like the heart. This segmentation allows the treatment to target harmful effects locally in cardiac tissues while avoiding systemic side effects that would occur with whole-body gene expression or continued dietary supplementation.
Solution Approach 2:
The patent creates a functional copy of the PGM1 gene with codon optimization to ensure proper expression in human cells. This copied and optimized gene sequence is delivered via AAV vectors to replace the defective endogenous PGM1 gene, providing a safe and effective treatment that restores enzyme function without introducing harmful mutations or requiring long-term dietary intervention.
3Reliability
If AAV-mediated gene therapy is used to deliver PGM1, then cardiac dysfunction progression is halted or reversed, but the complexity of gene therapy delivery increases
Solution Approach 1:
The patent employs AAV vectors that possess universal properties for efficient gene delivery across multiple tissue types, with particular optimization for cardiac tissue through specific serotypes (such as AAV9). This multi-functional vector system can deliver the PGM1 gene efficiently while incorporating codon-optimized sequences and tissue-specific regulatory elements, achieving reliable therapeutic outcomes without requiring overly complex delivery mechanisms.
Data Source
AI summary
Disclosed herein, are compositions and methods useful in expressing a functional PGM1 protein in a subject by administration of a recombinant adeno-associated virus vector containing a transgene encoding PGM1. Also disclosed herein are methods for treating a PGM1 gene deficiency in a subject in need thereof.